Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiol Therapeutics (CRDL) Share-based Compensation: 2021-2022

Historic Share-based Compensation for Cardiol Therapeutics (CRDL) over the last 2 years, with Sep 2022 value amounting to $147,287.

  • Cardiol Therapeutics' Share-based Compensation rose 3.52% to $147,287 in Q3 2022 from the same period last year, while for Sep 2022 it was $4.8 million, marking a year-over-year change of. This contributed to the annual value of $10.4 million for FY2024, which is 238.48% up from last year.
  • As of Q3 2022, Cardiol Therapeutics' Share-based Compensation stood at $147,287, which was up 105.57% from $71,647 recorded in Q2 2022.
  • Cardiol Therapeutics' Share-based Compensation's 5-year high stood at $3.6 million during Q4 2021, with a 5-year trough of $71,647 in Q2 2022.
  • Moreover, its 2-year median value for Share-based Compensation was $894,557 (2022), whereas its average is $1.2 million.
  • Data for Cardiol Therapeutics' Share-based Compensation shows a peak YoY increase of 3.52% (in 2022) and a maximum YoY decrease of 96.54% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Cardiol Therapeutics' Share-based Compensation stood at $3.6 million in 2021, then rose by 3.52% to $147,287 in 2022.
  • Its last three reported values are $147,287 in Q3 2022, $71,647 for Q2 2022, and $894,557 during Q1 2022.